Pelacarsen Lp(a)HORIZON trial results announced by Novartis confirm that the Phase III cardiovascular outcomes study did not meet its primary endpoint, marking a closely watched setback for lipoprotein(a)-lowering research. The trial, filed as an ad hoc announcement under Art. 53 LR, evaluated whether pelacarsen could reduce cardiovascular events in patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD) already receiving guideline-directed care.
The primary endpoint measured in the pelacarsen Lp(a)HORIZON trial results was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared with placebo. Novartis reported that lower Lp(a) levels were achieved with pelacarsen in the study population, but this reduction did not translate into a measurable decrease in cardiovascular events across the overall trial population.
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, said the Lp(a)HORIZON program was designed to answer one of cardiovascular medicine’s most important open questions: whether lowering Lp(a) reduces residual risk on top of optimized care. Aradhye acknowledged the outcome was disappointing, noting the results were “not the results we hoped for,” while emphasizing that the pelacarsen Lp(a)HORIZON trial results still advance scientific understanding of how Lp(a) reduction relates to cardiovascular outcomes and may help shape future risk-management strategies. Novartis also thanked the more than 8,000 participants and investigators involved in the study.
The study enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease in a randomized, placebo-controlled, double-blind, parallel-group, multi-center global design. Full data from the trial have not yet been released publicly; Novartis said the complete Lp(a)HORIZON dataset will be presented at an upcoming medical congress, where independent cardiologists and researchers will have the opportunity to review the findings in detail.
What the Pelacarsen Lp(a)HORIZON Trial Results Mean for Lp(a) Lowering
The pelacarsen Lp(a)HORIZON trial results represent one of the first large-scale, hard-outcomes tests of the long-standing hypothesis that pharmacologically lowering Lp(a) improves cardiovascular outcomes. While pelacarsen succeeded in lowering Lp(a) levels, the disconnect between biomarker reduction and clinical benefit in the overall population raises new questions for a therapeutic class that has drawn significant industry investment over the past decade.
Elevated Lp(a) is described by Novartis as an inherited, independent, and causal cardiovascular disease risk factor. Lp(a) levels are approximately 90% genetically determined and are largely unaffected by diet or lifestyle changes, distinguishing it from LDL cholesterol and other modifiable risk factors. Elevated Lp(a) can contribute to plaque buildup and arterial inflammation, which may lead to plaque rupture and downstream cardiovascular events.
According to the source data, approximately 20% of people worldwide carry elevated Lp(a), and nearly one-third of individuals with premature cardiovascular disease have elevated levels of the lipoprotein. There is currently no approved targeted treatment for elevated Lp(a). Both US and European cardiology guidelines recommend that all adults be tested for Lp(a) at least once in their lifetime, reflecting the biomarker’s growing clinical relevance even without an approved therapy to directly address it.
Pelacarsen Lp(a)HORIZON Trial Results: The Investigational Therapy Explained
Pelacarsen is an investigational antisense oligonucleotide (ASO) engineered to inhibit the production of lipoprotein(a) at its biological source, rather than clearing it after it circulates in the bloodstream. Novartis holds global rights to develop, manufacture, and commercialize pelacarsen under a license and collaboration agreement with Ionis Pharmaceuticals, the company that originated the antisense technology underlying the compound.
The Lp(a)HORIZON trial, registered as NCT04023552, is described as a Phase III, randomized, placebo-controlled, double-blind, parallel-group, multi-center global cardiovascular outcomes trial. It assessed the incidence of four-point major adverse cardiovascular events (MACE) in patients with elevated Lp(a) and established CVD. The primary endpoint was evaluated both in the overall population, defined as Lp(a) of 70 mg/dL or greater, and in a subpopulation with Lp(a) of 90 mg/dL or greater, a design intended to test whether a more highly elevated baseline might show a different treatment effect.
Novartis’ Cardiovascular Pipeline After the Pelacarsen Lp(a)HORIZON Trial Results
Novartis framed the pelacarsen Lp(a)HORIZON trial results within a broader, four-decade commitment to cardiovascular disease research, stating that the company remains focused on earlier intervention, expanding understanding of cardiovascular disease, and advancing what it described as an industry-leading pipeline. The company said it remains committed to cardiovascular innovation despite the trial’s outcome.
Beyond confirming the pelacarsen Lp(a)HORIZON trial results, Novartis has not disclosed a timeline for any regulatory filing decision related to pelacarsen, and the release does not specify next steps for the compound’s development program beyond the planned congress presentation. Pricing, commercial timelines, and any changes to the broader Lp(a) research program were also not disclosed in the source announcement. The company’s statement contains forward-looking language regarding pelacarsen and cautioned that actual outcomes may differ from any forward-looking statements due to clinical, regulatory, and commercial uncertainties.
Key Data From the Pelacarsen Lp(a)HORIZON Trial Results
The tables below summarize the pelacarsen Lp(a)HORIZON trial results alongside disclosed trial parameters, endpoint composition, and epidemiological context for elevated Lp(a), structured for quick reference and machine readability.
| Parameter | Detail |
|---|---|
| Trial name | Lp(a)HORIZON |
| Registration | NCT04023552 |
| Phase | Phase III |
| Design | Randomized, placebo-controlled, double-blind, parallel-group, multi-center, global |
| Enrollment | 8,323 patients |
| Population | Elevated Lp(a) with established cardiovascular disease |
| Sponsor | Novartis |
| Technology partner | Ionis Pharmaceuticals (license and collaboration agreement) |
| Primary endpoint result | Did not meet statistical significance vs. place |
